Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 192-199 , February 2010

Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes

  • L. Brazionis

      Affiliations

    • Department of Medicine, University of Melbourne, St Vincent's Hospital, Australia
    • These authors contributed equally.
    • Corresponding Author InformationCorresponding author at: The University of Melbourne, Department of Medicine, St Vincent's Hospital, P.O. BOX 2900, Fitzroy, VIC 3065, Australia. Tel.: +61 3 92882665; fax: +61 3 92882581.
    • ,
  • J. Yau

      Affiliations

    • Department of Medicine, University of Melbourne, St Vincent's Hospital, Australia
    • Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye and Ear Hospital, Victoria, Australia
    • These authors contributed equally.
    • ,
  • K. Rowley

      Affiliations

    • Onemda VicHealth Koori Health Unit, Centre for Health and Society, School of Population Health, University of Melbourne, Australia
    • ,
  • C. Itsiopoulos

      Affiliations

    • Department of Medicine, University of Melbourne, St Vincent's Hospital, Australia
    • ,
  • K. O’Dea

      Affiliations

    • Department of Medicine, University of Melbourne, St Vincent's Hospital, Australia
    • ,
  • T.Y. Wong

      Affiliations

    • Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye and Ear Hospital, Victoria, Australia
    • ,
  • A. Jenkins

      Affiliations

    • Department of Medicine, University of Melbourne, St Vincent's Hospital, Australia

Received 16 July 2009 ,Revised 9 November 2009 ,Accepted 9 November 2009.

References 

  1. Wong TY, Islam FM, Klein R, et al. Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest. Ophthalmol. Vis. Sci. 2006;47:2341–2350
  2. Wong TY, Kamineni A, Klein R, et al. Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch. Intern. Med. 2006;166:2388–2394
  3. Klein R, Klein BE, Moss SE, et al. The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX: the wisconsin epidemiologic study of diabetic retinopathy. Arch. Ophthalmol. 2004;122:76–83
  4. Sun C, Liew G, Wang JJ, et al. Retinal vascular caliber, blood pressure, and cardiovascular risk factors in an Asian population: the Singapore Malay eye study. Invest. Ophthalmol. Vis. Sci. 2008;49:1784–1790
  5. Liew G, Wang JJ, Duncan BB, et al. Low birthweight is associated with narrower arterioles in adults. Hypertension. 2008;51:933–938
  6. Brazionis L, Rowley K, Jenkins A, Itsiopoulos C, O’Dea K. Plasminogen activator inhibitor-1 activity in type 2 diabetes. A different relationship with coronary heart disease and diabetic retinopathy. Arterioscler. Thromb. Vasc. Biol. 2008;
  7. Giles GG. Epidemiology of food and disease: the Melbourne cohort study. Asia Pac. J. Clin. Nutr. 2004;13:S30
  8. World Health Organization (WHO) . Diabetes Mellitus: Report of a WHO Study Group.. Geneva: World Health Organization; 1999;
  9. Callaway CW. Obesity. Public Health Rep. 1987;102:26–29
  10. Wong TY, Knudtson MD, Klein R, Klein BE, Meuer SM, Hubbard LD. Computer-assisted measurement of retinal vessel diameters in the beaver dam eye study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology. 2004;111:1183–1190
  11. Wong TY. Is retinal photography useful in the measurement of stroke risk?. Lancet Neurol. 2004;3:179–183
  12. Parr JC, Spears GF. General caliber of the retinal arteries expressed as the equivalent width of the central retinal artery. Am. J. Ophthalmol. 1974;77:472–477
  13. Hubbard LD, Brothers RJ, King WN, et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the atherosclerosis risk in communities study. Ophthalmology. 1999;106:2269–2280
  14. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem. 2004;50:3–32
  15. Wong TY, Shankar A, Klein R, Klein BE. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes. Diabetes. 2004;53:179–184
  16. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int. J. Clin. Pract. 2005;59:102–106
  17. Nagi DK, Mohamed Ali V, Jain SK, Walji S, Yudkin JS. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians. Diabet. Med. 1996;13:59–64
  18. Hirano T, Kashiwazaki K, Moritomo Y, Nagano S, Adachi M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 1997;36:11–18
  19. Szelag B, Wroblewski M, Castenfors J, et al. Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes. Diabetes Care. 1999;22:1907–1908
  20. Kawagishi T, Matsuyoshi M, Emoto M, et al. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 1999;19:2509–2516
  21. Funk M, Endler G, Exner M, et al. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien. Klin. Wochenschr. 2005;117:707–710
  22. Nagi DK, Knowler WC, Hanson RL, Ali VM, Yudkin JS. Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in Pima Indians, south Asians and Europeans. Populations at varying risk of NIDDM and coronary artery disease. Thromb. Haemost. 1996;75:921–927
  23. Astrup AS, Tarnow L, Pietraszek L, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10years: association with mortality and decline of glomerular filtration rate. Diabetes Care. 2008;31:1170–1176
  24. Bosnyak Z, Forrest KY, Maser RE, Becker D, Orchard TJ. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh epidemiology of diabetes complications study. Diabet. Med. 2003;20:147–151
  25. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care. 1997;20:1304–1309
  26. Latron Y, Chautan M, Anfosso F, et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler. Thromb. 1991;11:1821–1829
  27. Morange PE, Aubert J, Peiretti F, et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes. 1999;48:890–895
  28. Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G, Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler. Thromb. Vasc. Biol. 1999;19:1361–1365
  29. Ersoy C, Kiyici S, Budak F, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 2008;81:56–60
  30. Jenkins AJ, Li W, Moller K, et al. Pre-enrichment of modified low density lipoproteins with alpha-tocopherol mitigates adverse effects on cultured retinal capillary cells. Curr. Eye Res. 1999;19:137–145
  31. Klein RL, Semler AJ, Baynes JW, Thorpe SR, Lyons TJ, Jenkins AJ. Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells. Ann. N. Y. Acad. Sci. 2005;1043:379–389
  32. Eisenberg S. Lipoproteins, cholesterol ester transport and atherogenesis. Monogr. Atheroscler. 1986;14:107–112
  33. Miyazaki H, Ogiku T, Sai H, Ohmizu H, Murakami J, Ohtani A. Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. Bioorg. Med. Chem. Lett. 2008;18:6419–6422
  34. Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr. Drug Targets. 2007;8:962–970

PII: S0168-8227(09)00478-1

doi: 10.1016/j.diabres.2009.11.007

Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 192-199 , February 2010

Article Tools